6503 ORAL Efficacy and safety results from BO17704, a randomised, placebo-controlled phase III study of bevacizumab in combination with cisplatin and gemcitabine in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC)

Impact of Third-Generation Drugs on the Activity of First-Line Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analytical Approach

“…In a similar study of gemcitabine-cisplatin compared with cisplatin alone, the ORRs were 30.4% and 11.1%, respectively; the risk for PD was 18% lower and the median survival duration was significantly longer in the gemcitabine arm [10]. Recent studies have investigated the benefit of adding a biological drug, namely, gefitinib (Iressa ® ; Astra-Zeneca Pharmaceuticals, Wilmington, DE), erlotinib (Tarceva ® ; OSI Pharmaceuticals, Inc., Melville, NY), or bevacizumab (Avas-tin ® ; Genentech Inc., South San Francisco, CA), to either cisplatin-gemcitabine [81][82][83] or carboplatin plus a taxane [84 -86]. Although these studies did not report PD rates, an overview of their results suggests that carboplatin-paclitaxel with or without the experimental agent usually produces numerically inferior outcomes in terms of both response and TTP.…”

“…Although these studies did not report PD rates, an overview of their results suggests that carboplatin-paclitaxel with or without the experimental agent usually produces numerically inferior outcomes in terms of both response and TTP. In particular, an interesting finding has emerged from the comparison of PFS rates in two very recent studies [83,86] of carboplatin-paclitaxel and cisplatin-gemcitabine with or without bevacizumab. Both demonstrated a significantly longer PFS time for bevacizumab-containing arms over chemotherapy alone; however, the hazard ratio for progression was shown to be lower in the former study, that is, with carboplatin-paclitaxel as the control arm [86].…”

Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer

“…Clinical data with the anti-VEGF monoclonal antibody, bevacizumab, plus first-line chemotherapy improved efficacy in patients with advanced NSCLC (Sandler et al, 2006;Manegold et al, 2007Manegold et al, , 2008, indicating that targeting angiogenesis through VEGF is a viable strategy. Furthermore, preclinical data suggest that concomitant inhibition of VEGF and PDGF signalling may improve antitumour activity compared with VEGF inhibition alone (Shikada et al, 2005;Potapova et al, 2006;Hasumi et al, 2007).…”

The Role of Bevacizumab in the Treatment of Non-Small Cell Lung Cancer: Current Indications and Future Developments

“…Among angiogenesis inhibitors, the anti-vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) bevacizumab (Avastin ; Genentech Inc., South San Francisco, CA) represents the most successful targeted therapy. In fact, in chemotherapy-naive advanced NSCLC patients with nonsquamous histology, the combination of bevacizumab with chemotherapy has demonstrated, in two large phase III randomized trials, better efficacy outcomes than with chemotherapy alone [8,9]. These represent the first evidence of improvement in treatment outcomes of chemotherapy with targeted therapies in the first-line treatment of advanced NSCLC.…”

“…In fact, bevacizumab, combined with chemotherapy, has already been demonstrated, in phase III randomized trials, to improve efficacy outcomes over those seen with chemotherapy alone in the treatment of advanced colorectal cancer, breast cancer, and NSCLC [8,9,27,28].…”